Mode
Text Size
Log in / Sign up
N/A N=37 Treatment

Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System

Peripheral Arterial Disease · Vascular Disease, Peripheral

Enrolled (actual)
37
Serious AEs
54.1%
Results posted
Aug 2023
Primary outcome: Primary: Number of Participants With Major Adverse Events (MAE) — 0 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Shockwave Medical, Inc.
Primary completion
Aug 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Major Adverse Events (MAE)
1
PRIMARY
Number of Lesions With Technical Success
43
SECONDARY
Number of Lesions With IVL Technical Success
28
SECONDARY
Number of Participants With Procedural Success
30
SECONDARY
Number of Participants With Clinically-driven Target Lesion Revascularization (TLR)
3
SECONDARY
Rutherford Category Reported as Change From Baseline
24
SECONDARY
Number of Participants With Major Adverse Events (MAE)
1
SECONDARY
Number of Participants With Clinically-driven Target Lesion Revascularization (TLR)
3
SECONDARY
Rutherford Category Reported as Change From Baseline
24
SECONDARY
Number of Participants With Primary Patency
21
SECONDARY
Number of Participants With Major Adverse Events (MAE)
1
SECONDARY
Number of Participants With Clinically-driven Target Lesion Revascularization (TLR)
3
SECONDARY
Ankle-brachial Index (ABI) Reported as Change From Baseline
0.3
SECONDARY
Rutherford Category Reported as Change From Baseline
24

Summary

Prospective, multi-center, single-arm study of the M5+ Peripheral IVL system to treat calcified peripheral arteries.

Eligibility Criteria

General Inclusion Criteria

  • Subject is able and willing to comply with all assessments in the study.
  • Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
  • Age of subject is > 18.
  • Rutherford Clinical Category 2, 3, 4 or 5 of the target limb(s).
  • Estimated life expectancy >1 year.
  • Subject is intended to undergo treatment with Shockwave M5+ Peripheral IVL System for de novo lesions of the ilio-femoropopliteal arteries.

Angiographic Inclusion Criteria

  • Single or multiple de novo target lesion(s) located from the common iliac to the femoropopliteal artery, in one or both limbs.
  • Target lesion reference vessel diameter is between 3.5mm and 8.0mm by visual estimate.
  • Target lesion is ≥70% stenosis by investigator via visual estimate.
  • Target lesion length is ≤200mm for lesions 70-99% stenosed. Target lesion can be all or part of the 200mm treated zone.
  • Chronic total occlusion, lesion length is ≤100mm of the total ≤200 mm target lesion.
  • Subject has at least one patent tibial vessel on the target leg with runoff to the foot, defined as no stenosis >50%.
  • Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is 2.5 mg/dL or >220 umol/L, unless on dialysis.
  • Subject is pregnant or nursing.
  • Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
  • Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
  • The planned use of specialty balloons, re-entry or atherectomy devices in the target lesion(s).

Angiographic Exclusion Criteria

  • In-stent restenosis within 10mm of the target zone.
  • Target lesions distal to the popliteal artery.
  • Evidence of aneurysm or thrombus in target vessel.
  • No calcium or mild calcium in the target lesion.
  • Target lesion within native or synthetic vessel grafts.
  • Subject has more than three target lesions requiring treatment.
  • Subject has significant non-target lesion (>50% stenosis or occlusion) within the target limb (e.g. iliac, common femoral or below-the-knee) not successfully treated prior to treatment of the target lesions.
  • Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04585763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search